<DOC>
	<DOC>NCT01294462</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese patients with acute coronary syndrome and a planned percutaneous coronary intervention (PCI).</brief_summary>
	<brief_title>Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision of signed informed consent Index event of nonST or ST segment elevation ACS Index event is an acute complication of percutaneous coronary intervention Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment Oral anticoagulation therapy that cannot be stopped The conditions associated with increased risk of bradycardiac events</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>coronary disease</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>